Effects of weight loss during a very low carbohydrate diet on specific adipose tissue depots and insulin sensitivity in older adults with obesity: a randomized clinical trial.
Journal
Nutrition & metabolism
ISSN: 1743-7075
Titre abrégé: Nutr Metab (Lond)
Pays: England
ID NLM: 101231644
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
01
2020
accepted:
22
07
2020
entrez:
21
8
2020
pubmed:
21
8
2020
medline:
21
8
2020
Statut:
epublish
Résumé
Insulin resistance and accumulation of visceral adipose tissue (VAT) and intermuscular adipose tissue (IMAT) place aging adults with obesity at high risk of cardio-metabolic disease. A very low carbohydrate diet (VLCD) may be a means of promoting fat loss from the visceral cavity and skeletal muscle, without compromising lean mass, and improve insulin sensitivity in aging adults with obesity. To determine if a VLCD promotes a greater loss of fat (total, visceral and intermuscular), preserves lean mass, and improves insulin sensitivity compared to a standard CHO-based/low-fat diet (LFD) in older adults with obesity. Thirty-four men and women aged 60-75 years with obesity (body mass index [BMI] 30-40 kg/m Participants lost an average of 9.7 and 2.0% in total fat following the VLCD and LFD, respectively ( Weight loss resulting from consumption of a diet lower in CHO and higher in fat may be beneficial for older adults with obesity by depleting adipose tissue depots most strongly implicated in poor metabolic and functional outcomes and by improving insulin sensitivity and the lipid profile. NCT02760641. Registered 03 May 2016 - Retrospectively registered.
Sections du résumé
BACKGROUND
BACKGROUND
Insulin resistance and accumulation of visceral adipose tissue (VAT) and intermuscular adipose tissue (IMAT) place aging adults with obesity at high risk of cardio-metabolic disease. A very low carbohydrate diet (VLCD) may be a means of promoting fat loss from the visceral cavity and skeletal muscle, without compromising lean mass, and improve insulin sensitivity in aging adults with obesity.
OBJECTIVE
OBJECTIVE
To determine if a VLCD promotes a greater loss of fat (total, visceral and intermuscular), preserves lean mass, and improves insulin sensitivity compared to a standard CHO-based/low-fat diet (LFD) in older adults with obesity.
DESIGN
METHODS
Thirty-four men and women aged 60-75 years with obesity (body mass index [BMI] 30-40 kg/m
RESULTS
RESULTS
Participants lost an average of 9.7 and 2.0% in total fat following the VLCD and LFD, respectively (
CONCLUSIONS
CONCLUSIONS
Weight loss resulting from consumption of a diet lower in CHO and higher in fat may be beneficial for older adults with obesity by depleting adipose tissue depots most strongly implicated in poor metabolic and functional outcomes and by improving insulin sensitivity and the lipid profile.
TRIAL REGISTRATION
BACKGROUND
NCT02760641. Registered 03 May 2016 - Retrospectively registered.
Identifiants
pubmed: 32817749
doi: 10.1186/s12986-020-00481-9
pii: 481
pmc: PMC7425171
doi:
Banques de données
ClinicalTrials.gov
['NCT02760641']
Types de publication
Journal Article
Langues
eng
Pagination
64Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK056336
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK079626
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL105349
Pays : United States
Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsK.F. serves on the scientific advisory board to Virta Health Corp and has stock options. He also serves on the scientific advisory board to Atkins Nutritionals. The other authors have nothing to disclose.
Références
Prog Lipid Res. 2008 Sep;47(5):307-18
pubmed: 18396172
Exp Gerontol. 2016 Dec 15;86:4-13
pubmed: 26994938
J Obes. 2011;2011:
pubmed: 20953373
Am J Clin Nutr. 2008 Jan;87(1):44-55
pubmed: 18175736
Am J Clin Nutr. 1992 Jul;56(1 Suppl):292S-293S
pubmed: 1615908
Am J Physiol Endocrinol Metab. 2019 May 1;316(5):E866-E879
pubmed: 30620635
Am J Physiol. 1979 Sep;237(3):E214-23
pubmed: 382871
JAMA. 2018 Feb 20;319(7):667-679
pubmed: 29466592
J Proteome Res. 2013 Dec 6;12(12):5801-11
pubmed: 24224694
Arch Intern Med. 2010 Jan 25;170(2):136-45
pubmed: 20101008
J Nutr. 2015 Jan;145(1):177S-83S
pubmed: 25527677
J Nutr Health Aging. 2014 May;18(5):532-8
pubmed: 24886741
N Engl J Med. 2003 May 22;348(21):2074-81
pubmed: 12761364
Acta Physiol Scand. 1970 Sep;80(1):11-8
pubmed: 5475323
Int J Endocrinol. 2018 Sep 4;2018:2751250
pubmed: 30254672
Health Aff (Millwood). 2005;24 Suppl 2:W5R30-41
pubmed: 16186149
Am J Clin Nutr. 2014 May;99(5):1059-65
pubmed: 24522448
Nutr Metab (Lond). 2006 Jan 31;3:9
pubmed: 16448570
Ann Intern Med. 2004 May 18;140(10):769-77
pubmed: 15148063
Ann Intern Med. 2005 Mar 15;142(6):403-11
pubmed: 15767618
J Pediatr Endocrinol Metab. 2012;25(7-8):697-704
pubmed: 23155696
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
Evid Based Complement Alternat Med. 2013;2013:760804
pubmed: 23573151
Metabolism. 2014 Oct;63(10):1257-64
pubmed: 25125349
Obesity (Silver Spring). 2013 Jun;21(6):1139-42
pubmed: 23671029
Obes Rev. 2010 Jan;11(1):11-8
pubmed: 19656312
Metabolism. 2012 Dec;61(12):1817-23
pubmed: 22748969
Am J Clin Nutr. 2013 Mar;97(3):552-60
pubmed: 23364001
Am J Physiol Endocrinol Metab. 2004 Nov;287(5):E842-7
pubmed: 15238354
Diabetes. 2018 Nov;67(11):2129-2136
pubmed: 30348819
JAMA. 2013 Sep 25;310(12):1263-73
pubmed: 24065013
Ageing Res Rev. 2017 May;35:200-221
pubmed: 27702700
Am J Clin Nutr. 2008 Jun;87(6):1590-5
pubmed: 18541544
J Clin Endocrinol Metab. 2000 Jul;85(7):2402-10
pubmed: 10902785
Int J Obes (Lond). 2012 Sep;36(9):1141-50
pubmed: 22410960
J Nutr. 2005 Jun;135(6):1339-42
pubmed: 15930434
Endocrinol Metab (Seoul). 2017 Jun;32(2):257-264
pubmed: 28555462
J Nutr. 2004 Apr;134(4):880-5
pubmed: 15051841